US 11,866,479 B2
HIV antibody derivatives with dual antiviral and immunomodulatory activities from CD4 and GP41
Jorge Carrillo Molina, Badalona (ES); Bonaventura Clotet Sala, Badalona (ES); and Julian M. Blanco Arbues, Badalona (ES)
Assigned to FUNDACIÓ PRIVADA INSTITUTE DE RECERA DE LA SIDA-CAIXA, Badalona (ES)
Appl. No. 15/777,666
Filed by AlbaJuna Therapeutics, S.L., Badalona (ES)
PCT Filed Nov. 19, 2016, PCT No. PCT/IB2016/001868
§ 371(c)(1), (2) Date Oct. 22, 2019,
PCT Pub. No. WO2017/085563, PCT Pub. Date May 26, 2017.
Prior Publication US 2021/0238252 A1, Aug. 5, 2021
Int. Cl. C07K 19/00 (2006.01); C07K 14/705 (2006.01); C07K 14/005 (2006.01); A61P 31/18 (2006.01); G01N 33/569 (2006.01); C07K 14/73 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); C07K 14/715 (2006.01); A61K 45/06 (2006.01)
CPC C07K 14/70514 (2013.01) [A61K 38/162 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61P 31/18 (2018.01); C07K 14/005 (2013.01); C07K 14/7158 (2013.01); C07K 19/00 (2013.01); G01N 33/56988 (2013.01); A61K 45/06 (2013.01); C07K 2319/30 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16033 (2013.01); G01N 2333/16 (2013.01)] 19 Claims
 
1. An antibody derivative comprising from N- to C-terminus:
(a) a human CD4 sequence comprising SEQ ID NO:1 and SEQ ID NO:2 or a sequence having at least 96% identity thereto,
(b) the Fc portion of a human IgG,
(c) a moiety consisting of a linker polypeptide of sequence (GGGGS)n wherein n=10, and
(d) a gp41-derived polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10 or a sequence having at least 96% identity thereto.